A Study of Clinical and Investigational Profile of Hirsute Women at a Tertiary Care Center in Western India

    January 2020 in “ Clinical Dermatology Review ”
    SuyogS Dhamale, PriyankaG Dhanotia, BelaJ Shah, SuyogS Dhamale, PriyankaG Dhanotia, BelaJ Shah
    TLDR Idiopathic hirsutism is the most common cause of hirsutism in women, followed by PCOS.
    The study at a tertiary care center in Western India examined 44 hirsute women, revealing that idiopathic hirsutism (IH) was the most common cause, followed by polycystic ovarian syndrome (PCOS). Alopecia was the most frequent associated condition, affecting 45.45% of participants. Elevated total testosterone was found in 25% of patients, mainly those with PCOS. The study underscored the need for comprehensive evaluation before diagnosing IH and highlighted the prevalence of polycystic ovarian morphology in PCOS patients. Despite its small sample size and single-center data, the study called for further research across different regions to enhance understanding of hirsutism.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 27 results

      community AA and Hirsutism but T levels are normal

      in Female  6 upvotes 4 years ago
      27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

      community Finasteride 5mg & Spironolactone 100mg

      in Female  2 upvotes 11 months ago
      A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  107 upvotes 4 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

      community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025

      in Treatment  121 upvotes 1 year ago
      Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

      community Does low HGH leading to hairloss?

      in Research/Science  12 upvotes 1 year ago
      The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

    Related Research

    2 / 2 results